Zurich Cantonal Bank
BIB icon

Zurich Cantonal Bank’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Zurich Cantonal Bank’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-60,000
Closed -$2.4M – 1001
2014
Q1 		$2.4M Buy
+60,000
New +$2.72M 0.07% 310

Other funds holding BIB

VCAM
Valentine Capital Asset Management Danville, California $89.6M AUM 0.84% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Zurich Cantonal Bank's BIB Position: Q2 2014 in Review

Zurich Cantonal Bank sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2014, closing a stake of 60,000 shares — an estimated $2.4M sold.

Zurich Cantonal Bank first reported a position in BIB in Q1 2014 and held it in 1 quarter. The position peaked at $2.4M in Q1 2014. 22 funds tracked by Wall St. Rank hold BIB as of Q2 2014.

  • Zurich Cantonal Bank reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2014 after selling out during the quarter.
  • Zurich Cantonal Bank sold 60,000 ProShares Ultra NASDAQ Biotechnology shares in Q2 2014, an estimated $2.4M.
  • Zurich Cantonal Bank first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2014 and held it in 1 quarter.
  • Zurich Cantonal Bank's ProShares Ultra NASDAQ Biotechnology position peaked at $2.4M in Q1 2014.
  • 22 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2014.

Based on Zurich Cantonal Bank's 13F filing for Q2 2014, filed 6 Aug 2014.